Login to Your Account


New Questions on Avastin, Lucentis, VEGF Trap-Eye

By Tom Wall

Monday, May 2, 2011
Physicians, patients and analysts had new questions following the release of first-year results from a two-year National Institutes of Health study that found Avastin (bevacizumab), an FDA-approved cancer drug commonly used off-label, as effective as FDA-approved Lucentis (ranibizumab) in treating age-related macular degeneration (AMD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription